ArticleExperimental and therapeutic medicine2023

Hyperprogressive disease after immune checkpoint inhibitor therapy in a patient with non‑small cell lung cancer who harbors a TGFBR2 mutation: A case report.

Xiaofang Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.